TY - JOUR T1 - B-Raf inhibition in conjunctival melanoma cell lines with PLX 4720 JF - British Journal of Ophthalmology JO - Br J Ophthalmol SP - 1739 LP - 1745 DO - 10.1136/bjophthalmol-2015-306689 VL - 99 IS - 12 AU - Aline I Riechardt AU - Anna-Karina B Maier AU - Anika Nonnenmacher AU - Nadine Reichhart AU - Ulrich Keilholz AU - Norbert Kociok AU - Olaf Strauß AU - Antonia M Joussen AU - Enken Gundlach Y1 - 2015/12/01 UR - http://bjo.bmj.com/content/99/12/1739.abstract N2 - Purpose Mutations in the gene coding for the kinase B-Raf are associated with tumour growth in conjunctival melanoma. The purpose of this study is to explore effects of pharmacological B-Raf inhibition in conjunctival melanoma cell lines.Methods The B-Raf genotypes were assessed by PCR and subsequent sequencing. Cytotoxicity, cell viability, proliferation, apoptosis rate and phosphorylation rate of ERK and Akt were analysed in three different conjunctival melanoma cell lines under the influence of the B-Raf inhibitor PLX 4720 at various concentrations.Results The cell lines CRMM-1 and CM2005.1 showed the B-Raf V600E mutation, whereas CRMM-2 expressed a B-Raf wild type. CM2005.1 was highly sensitive to PLX 4720, showing a complete cytotoxic effect for >1 µM, as well as a significant concentration-dependent reduction of the proliferation rate and viability rate. Even though CRMM-1 also carries the B-Raf V600E mutation, it did not react as sensitive to PLX 4720 inhibition as CM2005.1, but showed a significant concentration-dependent reduction regarding proliferation and viability. PLX 4720 had only slight impact on CRMM-2 in high concentrations (10 µM) regarding cytotoxicity, proliferation and viability. Fluorescence-activated cell sorting analysis revealed that PLX 4720 acted predominantly antiproliferative and not via an induction of apoptosis. The phosphorylation rate of ERK was significantly reduced in CRMM-1 and CM2005.1, while it remained unchanged in CRMM-2. The phosphorylation rate of Akt was significantly elevated in CRMM-2.Conclusions Proliferation inhibition of conjunctival melanoma cells by PLX 4720 depends on their B-Raf genotype. Therefore, therapeutic application of B-Raf inhibitors should take into account the specific B-Raf genotype. ER -